These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 16639745)

  • 1. Multiple molecular dynamics simulations of human p450 monooxygenase CYP2C9: the molecular basis of substrate binding and regioselectivity toward warfarin.
    Seifert A; Tatzel S; Schmid RD; Pleiss J
    Proteins; 2006 Jul; 64(1):147-55. PubMed ID: 16639745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding.
    Haining RL; Jones JP; Henne KR; Fisher MB; Koop DR; Trager WF; Rettie AE
    Biochemistry; 1999 Mar; 38(11):3285-92. PubMed ID: 10079071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crystal structure of human cytochrome P450 2C9 with bound warfarin.
    Williams PA; Cosme J; Ward A; Angove HC; Matak Vinković D; Jhoti H
    Nature; 2003 Jul; 424(6947):464-8. PubMed ID: 12861225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9.
    Dickmann LJ; Locuson CW; Jones JP; Rettie AE
    Mol Pharmacol; 2004 Apr; 65(4):842-50. PubMed ID: 15044613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effector-mediated alteration of substrate orientation in cytochrome P450 2C9.
    Hummel MA; Gannett PM; Aguilar JS; Tracy TS
    Biochemistry; 2004 Jun; 43(22):7207-14. PubMed ID: 15170358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.
    He M; Korzekwa KR; Jones JP; Rettie AE; Trager WF
    Arch Biochem Biophys; 1999 Dec; 372(1):16-28. PubMed ID: 10562412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the human CYP2C9*13 variant activity reduction: a molecular dynamics simulation and docking study.
    Zhou YH; Zheng QC; Li ZS; Zhang Y; Sun M; Sun CC; Si D; Cai L; Guo Y; Zhou H
    Biochimie; 2006 Oct; 88(10):1457-65. PubMed ID: 16740353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced catalytic activity of human CYP2C9 natural alleles for gliclazide: molecular dynamics simulation and docking studies.
    Banu H; Renuka N; Vasanthakumar G
    Biochimie; 2011 Jun; 93(6):1028-36. PubMed ID: 21356265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants.
    Melet A; Marques-Soares C; Schoch GA; Macherey AC; Jaouen M; Dansette PM; Sari MA; Johnson EF; Mansuy D
    Biochemistry; 2004 Dec; 43(49):15379-92. PubMed ID: 15581350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis.
    Sano E; Li W; Yuki H; Liu X; Furihata T; Kobayashi K; Chiba K; Neya S; Hoshino T
    J Comput Chem; 2010 Nov; 31(15):2746-58. PubMed ID: 20839301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. P450 on drugs.
    Jabri E
    Nat Struct Biol; 2003 Aug; 10(8):587. PubMed ID: 12886290
    [No Abstract]   [Full Text] [Related]  

  • 12. Functional analysis of phenylalanine residues in the active site of cytochrome P450 2C9.
    Mosher CM; Hummel MA; Tracy TS; Rettie AE
    Biochemistry; 2008 Nov; 47(45):11725-34. PubMed ID: 18922023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of arginine 97 and lysine 72 as determinants of substrate specificity in cytochrome P450 2C9 (CYP2C9).
    Davies C; Witham K; Scott JR; Pearson A; DeVoss JJ; Graham SE; Gillam EM
    Drug Metab Dispos; 2004 Apr; 32(4):431-6. PubMed ID: 15039296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative binding models for CYP2C9 based on benzbromarone analogues.
    Locuson CW; Rock DA; Jones JP
    Biochemistry; 2004 Jun; 43(22):6948-58. PubMed ID: 15170332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9.
    Locuson CW; Gannett PM; Tracy TS
    Arch Biochem Biophys; 2006 May; 449(1-2):115-29. PubMed ID: 16545770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrochemical characterisation of the human cytochrome P450 CYP2C9.
    Johnson DL; Lewis BC; Elliot DJ; Miners JO; Martin LL
    Biochem Pharmacol; 2005 May; 69(10):1533-41. PubMed ID: 15857618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward understanding the inactivation mechanism of monooxygenase P450 BM-3 by organic cosolvents: a molecular dynamics simulation study.
    Roccatano D; Wong TS; Schwaneberg U; Zacharias M
    Biopolymers; 2006 Dec; 83(5):467-76. PubMed ID: 16862534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of CYP199A2, a para-substituted benzoic acid oxidizing cytochrome P450 from Rhodopseudomonas palustris.
    Bell SG; Xu F; Forward I; Bartlam M; Rao Z; Wong LL
    J Mol Biol; 2008 Nov; 383(3):561-74. PubMed ID: 18762195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part II.
    Mo SL; Zhou ZW; Yang LP; Wei MQ; Zhou SF
    Curr Drug Metab; 2009 Dec; 10(10):1127-50. PubMed ID: 20167000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural evidence for a functionally relevant second camphor binding site in P450cam: model for substrate entry into a P450 active site.
    Yao H; McCullough CR; Costache AD; Pullela PK; Sem DS
    Proteins; 2007 Oct; 69(1):125-38. PubMed ID: 17598143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.